Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome
Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 5463-5475
DOI: 10.1111/dom.70781 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 20.04.2026. Verfasst von Evan Zeitler und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Metabolic Syndrome, Hyperaldosteronism, Cardiovascular Diseases, Cardio-Renal Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS.
Abstract (Originalsprache)
Cardiovascular‐kidney‐metabolic (CKM) syndrome is defined by the pathologic interconnections between obesity, diabetes, chronic kidney disease and cardiovascular disease. An important and underrecognized pathophysiologic factor underlying CKM syndrome is obesity‐induced aldosterone excess. This excess aldosterone causes structural and functional alterations in the kidneys, heart and vasculature promoting development of chronic kidney disease, cardiovascular disease and heart failure. Inhibition of aldosterone signalling is a pillar in the treatment approach to CKM syndrome. Pharmacologic options include renin‐angiotensin‐aldosterone system (RAAS) inhibitors, angiotensin receptor‐neprilysin inhibitors and steroidal (such as spironolactone) or non‐steroidal (currently only finerenone) mineralocorticoid receptor antagonists. Additionally, aldosterone synthase inhibitors are currently in development. Effective anti‐obesity medications such as glucagon‐like peptide‐1 receptor agonists inhibit aldosterone production due to their effects on adipocytes and in the kidneys. RAAS inhibition is also used to optimize the long‐term management of CKM syndrome. Future research should seek to characterize the benefits of combination therapies for aldosterone excess and determine which subgroups of patients most benefit from aldosterone‐targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
- University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Northwestern Medical Group, Lake Forest, Illinois, USA.
- Endeavor Health (NorthShore Hospitals)/University of Chicago, Skokie, Illinois, USA.
ORCID-Profile: Evan Zeitler, Klara R Klein, Ildiko Lingvay
Förderung
- NCATS NIH HHS
Zitieren
APA
Zeitler, E., Klein, K. R., Lingvay, I., Pick, A., & Billings, L. K. (2026). Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome. Diabetes, Obesity and Metabolism, 28(7), 5463-5475. https://doi.org/10.1111/dom.70781
Vancouver
Zeitler E, Klein KR, Lingvay I, Pick A, Billings LK. Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome. Diabetes, Obesity and Metabolism. 2026;28(7):5463-5475. doi:10.1111/dom.70781
BibTeX
@article{Zeitler2026,
author = {Zeitler, Evan and Klein, Klara R and Lingvay, Ildiko and Pick, Anthony and Billings, Liana K},
title = {Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {7},
pages = {5463--5475},
doi = {10.1111/dom.70781}
}
EUVIMED